Download PDF
CC BY-NC-ND 4.0 · South Asian J Cancer 2014; 03(04): 203-205
DOI: 10.4103/2278-330X.142961
LEUKEMIAS : Original Article

Response to imatinib mesylate in childhood chronic myeloid leukemia in chronic phase: In pursuit of perfection

Vijay Gandhi Linga
Department of Medical Oncology, Nizams Institute of Medical Science, Hyderabad
,
Ranga Raman Ganta
Department of Medical Oncology, Nizams Institute of Medical Science, Hyderabad
,
Krishnamani Iyer Kalpathi
Department of Medical Oncology, Nizams Institute of Medical Science, Hyderabad
,
Sadashivudu Gundeti
Department of Medical Oncology, Nizams Institute of Medical Science, Hyderabad
,
Senthil J. Rajappa
Department of Medical Oncology, Basavatarakam Indo American Cancer Hospital and Research Institute, Hyderabad
,
Raghunadharao Digumarti
Director, Tata Memorial Hospital, Aganampudi, Vishakhapatnam, Andhra Pradesh
,
Tara Roshni Paul
Department of Pathology, Nizams Institute of Medical Science, Hyderabad
,
Ashwani Tandon
Department of Pathology, Nizams Institute of Medical Science, Hyderabad
› Author Affiliations Source of Support: Nill.
› Further Information
  PDF Download Permissions and Reprints

Abstract

Introduction: Childhood chronic myeloid leukemia (CML) accounts for less than 3% of all childhood leukemias, hence, data on imatinib (IM) in adult CML patients has been largely extrapolated to children. We have analyzed our data to add to the existing literature. Aims: Primary objective is to assess the progression-free survival (PFS). Secondary objective are cytogenetic response, overall survival (OS), and toxicities. Settings and Design: This is a retrospective analysis from the case records from a single institution. Materials and Methods: Institutional ethics committee approval was obtained. All the children diagnosed CML in chronic phase (CML-CP) aged less than 18 years registered between 2000 and 2009 were enrolled. All the patients were started on IM at 260 mg/m 2 . Statistical Analysis: Kaplan-Meier curves were used to calculate the PFS and OS. Results: There were 64 children with median age of 13 years (range, 1-18) with male predominance (male:female (M: F) - 1.85:1). Sixty-one patients (95.4%) achieved complete hematological response (CHR) at median of 8 weeks. Thirty-seven (57.8%) patients had evaluation of cytogenetic response and were subjects for outcome analysis. The median time to best cytogenetic response evaluation was 13 months (range, 4-52). Twenty-nine patients (78.3%) achieved complete cytogenetic response (CCyR). At a median follow-up of 36 months (range 5-75), 21 (56.8%) remained progression free and 35 (94.5%) are alive. Adverse events were tolerable. Conclusions: PFS at a median follow-up of 36 months is 56.8% and OS 94.5%.

Key words

Childhood chronic myeloid leukemia - cytogenetic responses - imatinib mesylate - survival


Publication History

Article published online:
31 December 2020

© 2014. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. https://creativecommons.org/licenses/by-nc-nd/4.0/.

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Andolina JR, Neudorf SM, Corey SJ. How I treat childhood CML. Blood 2012;119:1821-30.
  • 2 Rastogi MV, Stork L, Druker B, Blasdel C, Nguyen T, Boston BA. Imatinib mesylate causes growth deceleration in pediatric patients with chronic myelogenous leukemia. Pediatr Blood Cancer 2012;59:840-5.
  • 3 Millot F, Baruchel A, Guilhot J, Petit A, Leblanc T, Bertrand Y, et al. Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: Results of the French national phase IV trial. J Clin Oncol 2011;29:2827-32.
  • 4 Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013;122:872-84.
  • 5 Goteke VK, Maddi RN, Thota NK, Coca P, Nagalla B, Linga VG, et al. An anthropometric study in children with chronic myeloid leukemia on imatinib. J Clin Oncol 2012;30.
  • 6 Millot F, Traore P, Guilhot J, Nelken B, Leblanc T, Leverger G, et al. Clinical and biological features at diagnosis in 40 children with chronic myeloid leukemia. Pediatrics 2005;116:140-3.
  • 7 Champagne MA, Capdeville R, Krailo M, Qu W, Peng B, Rosamilia M, et al. Children′s Oncology Group phase I study. Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: Results from a Children′s Oncology Group phase I study. Blood 2004;104:2655-60.
  • 8 Kolb EA, Pan Q, Ladanyi M, Steinherz PG. Imatinib Mesylate in Philadelphia chromosome- positive leukemia of childhood. Cancer 2003;98:2643-50.
  • 9 Millot F, Guilhot J, Nelken B, Leblanc T, De Bont ES, Békassy AN, et al. Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation. Leukemia 2006;20:187-92.
  • 10 Ghadyalpatil N, Banawali S, Kurkure P, Arora B, Bansal S, Amare P. Efficacy and tolerability of imatinib mesylate in pediatric chronic myeloid leukemia in a large cohort: Results from a tertiary care referral center in India. J Clin Oncol 2009;27:15s.
  • 11 Lakshmaiah KC, Bhise R, Purohit S, Abraham LJ, Lokanatha D, Suresh TM, et al. Chronic myeloid leukemia in children and adolescents: Results of treatment with imatinib mesylate. Leuk Lymphoma 2012;53:2430-3.
  • 12 Biswajit D, Rejiv R, Manjunath N, Prasad G, Lakshmi S, Devika P, et al. Imatinib mesylate experience of young patients with chronic myeloid leukemia in chronic phase-Care to cure. J Clin Oncol 2009;27:15.
  • 13 Rajappa S, Varadpande L, Paul T, Jacob R, Digumarti R. Imatinib mesylate in early chronic phase chronic myeloid leukemia: Experience from a developing country. Leuk Lymphoma 2008;49:554-8.
  • 14 Agarwal MB, Agarwal UM, Rathi SS, Masurkar S, Zaveri B. Report of chronic myeloid leukemia in chronic phase from Ashirwad Hematology Centre, Mumbai, 2002-2009. Indian J Med Paediatr Oncol 2013;34:199-203.
  • 15 Andreas H, Timothy PH, Jerald PR, O′Brien SG, Guilhot F, Goldman JM, et al. International randomized study of interferon versus STI571 (IRIS) 7-year follow-up: Sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (IM) Blood 2008;112:186.